There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dynavax (DVAX) and Ascendis Pharma (ASND) with bullish sentiments.
Dynavax (DVAX)
In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Dynavax, with a price target of $30. The company’s shares closed on Friday at $4.82, close to its 52-week low of $4.69.
According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 4.5% and a 44.9% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Phasebio Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.
Currently, the analyst consensus on Dynavax is a Strong Buy with an average price target of $23.67, which is a 391.1% upside from current levels. In a report issued on May 24, William Blair also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Ascendis Pharma (ASND)
In a report released today, Liana Moussatos from Wedbush maintained a Buy rating on Ascendis Pharma, with a price target of $223. The company’s shares closed on Friday at $124.66, close to its 52-week high of $131.76.
According to TipRanks.com, Moussatos ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -8.1% and a 33.0% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Allena Pharmaceuticals Inc, and Aquestive Therapeutics Inc.
Ascendis Pharma has an analyst consensus of Strong Buy, with a price target consensus of $174.60, a 40.1% upside from current levels. In a report issued on May 31, Canaccord Genuity also maintained a Buy rating on the stock with a $144 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
